



28 March 2022

For Immediate Release

MICROBIO ANNOUNCES CAPITAL RAISE TO LAUNCH REVOLUTIONARY BLOODSTREAM INFECTION (BSI) TEST IN EUROPE

Microbio (Brisbane, Australia) today is pleased to announce that following positive domestic pilot study results, its market entry plans for its flagship InfectID-BSI test, which has the potential for significant improvement in detecting bloodstream infection and sepsis, the world's biggest killer.

Bloodstream infection (BSI) and sepsis result in 11 million deaths annually, killing more people than all forms of cancer. InfectID-BSI is an in vitro diagnostic test which significantly improves patient outcomes by telling clinicians within three hours of taking a blood sample which infection to treat.

Microbio has appointed the Landrich Group to manage clinical evaluation trials across four sites in the USA, India, South America and Australia with plans to submit the data generated to secure marketing clearance in Europe, India, USA and Australia.

The company has now commenced a capital raise prior to the mid-year launch of InfectID-BSI in the European market. This will be followed by launch of the product in the India, USA, Australia and into a number of Asian markets.

Microbio CEO Paul Carboon said this capital raise facilitates the clinical evaluation trials, increase commercialisation resources, prepare for domestic and international manufacturing and offset anticipated initial marketing and distribution expenses.

"The launch of our test is keenly anticipated," Mr Carboon said. "It has been 16 years in development and thanks to the support of key investors and tireless work by our scientific and administrative team we are within weeks of going to market which is a major milestone for the company".

"We are also delighted to have appointed WG Partners as our corporate advisors for what will be our last capital raise before we are in the market and generating income. WG Partners will provide Microbio with a range of advisory services to help the company deliver on its ambitions over the next few years. The track record of London based healthcare specialist investment bank WG Partners speaks for itself having completed transactions with a total value of £8.2 billion (A\$144 billion) in the past 10 years."

The current 'gold standard' method to identify the causative pathogen is a slow, two-step blood culturing and identification process that takes between 12 hours and several days and has limited sensitivity. Microbio's InfectID-BSI provides the potential for early BSI/sepsis diagnosis and therefore earlier use of optimal antimicrobials, which is likely to reduce the length of hospital stays and healthcare costs. The diagnostic test identifies 26 common BSI/sepsis-causing pathogens, using Real-Time Polymerase Chain Reaction (RT-PCR) instruments, which are open hardware platforms used in pathology labs around the world.

"We are excited that commercialisation is now imminent and that we are a step closer to providing this powerful diagnostic tool to clinicians across the globe." Mr Carboon said

Potential investors are encouraged to contact the company at info@microbio.com.au.

-Ends-



About Microbio

Microbio is an Australian scale-up biotechnology company based in Brisbane. The team at Microbio has brought together the latest advances in bioinformatics, genomics and molecular microbiology to develop a unique and revolutionary pathogen detection test. The Microbio team is working tirelessly to deliver their game-changing new test to the millions of patients who will benefit from better pathogen diagnosis. Microbio is actively seeking partners worldwide, especially in population health and virology, who will integrate this new information into their proactive regional and corporate testing protocols. Additionally, Microbio is looking to work with pathology laboratory partners who can help deliver these highly specific results faster and to remote locations to improve health, regardless of a patient's location.

About InfectID®

InfectID® is a diagnostic technology that detects and identifies bacterial, fungal, and viral targets. The test targets Single Nucleotide Polymorphisms (SNPs), the pathogen's DNA 'fingerprint', found at a specific point in each pathogen's genetic code. By focusing on SNPs rather than the whole genome, the process is fast, inexpensive, highly sensitive and can be adapted to target different pathogens. The technology was refined and became the foundation of Microbio's flagship product: InfectID-Bloodstream Infection. InfectID-BSI uses real-time Polymerase Chain Reaction (qPCR) to identify sepsis-causing pathogen species directly from blood without the need for pre-culture.

Microbio Founders

Paul Carboon | Executive Director, Founder and Chief Executive Officer

Paul has 30 years of commercialisation experience. In the technology sector, Paul brings deep understanding of commercial and product management as well as product development and been an executive for over 10 years. Paul has PMBOK in Project Management, GAICD, and has completed CEO Master Classis and is a leader in biotechnology innovation. He currently serves on the AusMedtech national advisory group and. Paul is also an Honorary Fellow of Biotechnology at Melbourne University.

Dr Flavia Huygens | Executive Director, Founder and Chief Scientific Officer

Flavia's 30-year teaching and research career has focused on molecular microbiology, with a particular focus on human pathogens. Flavia's expertise and exceptional ability to bring together emerging technology in molecular microbiology, genomics, proteomics and bioinformatics have culminated in the creation of InfectID.